A Thieno[3,2-D] pyrimidine class of p110α/GDH1 dual inhibitor SBS-873 suppresses TNBC growth by inhibiting PI3K/mTOR signaling and inducing ferroptosis through glutathione depletion.
Findings identify SBS-873 as a first-in-class dual inhibitor targeting both p110α and GDH1, offering a promising therapeutic strategy that simultaneously disrupts proliferative signaling, metabolic adaptation, and metastatic potential in TNBC.
Abstract
Background
Genetic alterations in phosphoinositide 3-kinase (PI3K) signaling are frequently observed in triple-negative breast cancer (TNBC), with the p110α subunit being the most mutated. Although this identifies p110α as a promising therapeutic target, selective inhibitors have demonstrated limited efficacy. Therefore, this study aimed to investigate the therapeutic potential and underlying mechanisms of SBS-873, a novel thieno[3,2-D]pyrimidine-based p110α inhibitor.
Methods
SBS-873 antitumor activity was evaluated in vitro and in TNBC xenograft models. The docking and biochemical assays confirmed the binding affinity of the compound. Protein and mRNA expression were analyzed by Western blotting and qRT-PCR, with immunofluorescence and immunohistochemistry confirming protein levels. Metabolic function was assessed using Seahorse analysis. Oxidative stress and lipid peroxidation were measured through the reduced glutathione test and malondialdehyde assay, while gene knockout validated the mechanism.
Results
SBS-873 exhibited broad antiproliferative activity across multiple cancer cell lines, with marked selectivity toward TNBC cells while sparing non-tumorigenic mammary cells. Mechanistically, SBS-873 suppressed the PI3K/AKT/mTOR signaling pathway by downregulating p110α and concurrently inhibited GDH1, a critical regulator of glutamine metabolism, redox homeostasis, and epithelial-mesenchymal transition (EMT). GDH1 inhibition resulted in glutathione depletion, GPX4 impairment, and increased lipid peroxidation, ultimately inducing ferroptotic cell death. In vivo, SBS-873 significantly reduced tumor growth in TNBC xenografts without observable toxicity, accompanied by suppression of both p110α and GDH1.
Conclusion
These findings identify SBS-873 as a first-in-class dual inhibitor targeting both p110α and GDH1, offering a promising therapeutic strategy that simultaneously disrupts proliferative signaling, metabolic adaptation, and metastatic potential in TNBC.
Compound 42D represents a promising molecule as an anti-cancer agent against colon, hepatocellular, and gallbladder cancers targeting the Wnt/β-catenin/TCF4 signaling pathway.
P. Murumkar, K. Neogi, Premlal S Meher et al.· Future Medicinal Chemistry· 0 citations
Although rapid systemic clearance currently limits its in vivo application, the potent cellular efficacy of B7 highlights its utility as a dual PI3K/HDAC lead compound, providing a distinct chemical scaffold for further structural optimization.
Wei-Xu Wang, Naziyila Shayilan, Xi-Jin Qi et al.· European journal of medicina...· 0 citations
The aim of this study was to evaluate in vivo antitumor activity of CTO, a novel, oral small molecule orotate formulation of carboxyamidotriazole (CAI). The antiproliferative and antimetastatic properties of CTO are driven by the inhibition of calcium influx through receptor-operated channels. By disrupting calci...
R. Karmali, Romina Walter, J. Gojo et al.· Cancer Research· 0 citations
Simultaneous inhibition of CDK2 and TRKA presents a promising therapeutic avenue for cancer treatment, capitalizing on the critical roles of CDK2 in cell cycle regulation and TRKA in tumor cell survival and progression. In continuation of our previous work on dual CDK2/TRKA inhibitors, two series of pyrazolo[1,5-a]pyri...
Mohamed H. Attia, Deena S. Lasheen, Nermin Samir et al.· RSC Advances· 0 citations
Targeting the crosstalk between histone methyltransferases G9a and EZH2 represents a promising strategy for cancer therapy. To improve upon our previously reported dual inhibitor SU08, we rationally designed and synthesized five series (SU, UA, UB, N, and L) of novel G9a/EZH2 dual inhibitors, incorporating diverse pyri...